Skip to main content

Table 1 LCS6 genotype frequencies in controls, individuals with polyps and CRC patients

From: Let-7 miRNA-binding site polymorphism in the KRAS 3UTR; colorectal cancer screening population prevalence and influence on clinical outcome in patients with metastatic colorectal cancer treated with 5-fluorouracil and oxaliplatin +/− cetuximab

Study population Genotype Frequency
Controls Wild-type (TT) 288/358 (80%)
Variant (TG/GG) 70/358 (20%)
Individuals with polyps Wild-type (TT) 851/1060 (80%)
Variant (TG/GG) 209/1060 (20%)
CRC patients Wild-type (TT) 151/197 (77%)
  Variant (TG/GG) 46/197 (23%)